Blackstone Life Sciences is a private equity investment strategy based in Cambridge, Massachusetts. The firm focuses on financing products in late-stage clinical development owned by life sciences companies, including pharmaceutical corporate collaborations, pre-approval royalties, and other opportunistic life sciences investments. Its goal is to bring vital medicines and technologies to market by designing, funding, and executing clinical trials for products generally in late-stage development. They collaborate with pharmaceutical, biotech, and medical technology companies to address unmet medical needs and fill a funding void in the industry.